TargetedTherapy - Drugonomy™ https://drugonomy.com Trusted source for drug knowledge Fri, 13 Feb 2026 09:42:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 https://drugonomy.com/wp-content/uploads/2026/01/Drugs-EMRC21-1-150x150.png TargetedTherapy - Drugonomy™ https://drugonomy.com 32 32 Camzyos https://drugonomy.com/2026/02/13/camzyos/ https://drugonomy.com/2026/02/13/camzyos/#respond Fri, 13 Feb 2026 09:42:01 +0000 https://drugonomy.com/?p=11305 What is Camzyos?

Camzyos (mavacamten) is a prescription medicine used to treat symptomatic obstructive hypertrophic cardiomyopathy (HCM), helping improve shortness of breath and the ability to be active.  Camzyos is a cardiac myosin inhibitor that relaxes heart muscles so the heart can fill with more blood and pump blood around your body more effectively.

In obstructive hypertrophic cardiomyopathy (HCM), the walls of the heart become excessively thickened and stiff. This reduces blood flow from the heart to your body, which causes symptoms of shortness of breath, rapid heartbeat, feeling light-headed, chest pain, fainting, and tiredness. Camzyos relaxes the heart muscles and reduces heart obstruction, which improves your ability to be active and other symptoms.

How does Camzyos work?

The heart pumps blood around the body as heart muscles contract and release. Heart muscles contract when two proteins called myosin and actin join together, and then muscles relax when myosin and actin are not joined. In obstructive HCM, too many myosin and actin connect, making the heart contract too much, thickening the heart walls, reducing blood flow from the heart, and causing symptoms.

Camzyos’s mechanism of action is a cardiac myosin inhibitor that works by binding to the myosin protein, which stops the actin proteins from binding to it. As a result, the heart muscle relaxes, the heart fills with more blood, and it can pump more effectively. Camzyos is an allosteric and reversible inhibitor selective for cardiac myosin.

Camzyos Indications

Camzyos is indicated for adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) to help improve functional capacity and symptoms. It can be used in patients with New York Heart Association (NYHA) class II-III obstructive HCM. Camzyos became an FDA-approved medicine on April 28, 2022.

Camzyos side effects

Common Camzyos side effects

Common Camzyos side effects include dizziness (27%) or fainting (6%).

Serious Camzyos side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Camzyos may cause serious side effects. Call your doctor at once if you have:

  • heart failure symptoms, such as shortness of breath, chest pain, tiredness, swelling in your legs, rapid weight gain, or racing or pounding heartbeats.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects.

Camzyos REMS program

Camzyos is only available through the Camzyos REMS program, which is required by the FDA to monitor the safe use of this medication. The REMS  (Risk Evaluation and Mitigation Strategy) program is required as this medicine can cause the heart muscles to become too relaxed, which increases the risk of heart failure.  Your doctor will review and discuss the REMS Patient Brochure with you and talk to you about how to enroll in the program.

Warnings

Camzyos may cause serious side effects, and carries a Boxed Warning for a risk of heart failure.

Heart failure:

Heart failure is a condition where the heart cannot pump with enough force. Heart failure is a serious condition that can lead to death. You must have echocardiograms before you take the first dose and also during your treatment with this medicine. This is important to help your healthcare provider understand how your heart is responding to this medicine. People who develop a serious infection or irregular heartbeat have a greater risk of heart failure during treatment.

Call your doctor at once if you have shortness of breath, chest pain, tiredness, swelling in your legs, rapid weight gain, or racing or pounding heartbeats.

The risk of heart failure is also increased when Camzyos is taken with certain other medicines. Tell your healthcare provider about the medicines you take, both prescribed and obtained over-the-counter, before and during treatment.

Because of the serious risk of heart failure, this medicine is only available through a restricted program called the Camzyos Risk Evaluation and Mitigation Strategy (REMS) Program.

See Camzyos side effects for information about side effects.

It is not known if Camzyos is safe and effective in children.

Before taking this medicine

Your treatment plan may change if you also use certain other medications such as:

  • nefazodone;
  • St. John’s wort;
  • an antibiotic eg.clarithromycin, rifabutin, rifampin, rifapentine, telithromycin;
  • antifungal medicine eg. itraconazole, ketoconazole;
  • antiviral medicine for HIV or hepatitis C eg. boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, ombitasvir, paritaprevir saquinavir, telaprevir, tipranavir;
  • cancer medicine eg. apalutamide, enzalutamide, mitotane;
  • seizure medicine eg. carbamazepine, oxcarbazepine, phenytoin, primidone;
  • steroid medicine eg. dexamethasone, prednisone;

Tell your doctor if you have ever had:

  • an irregular heartbeat;
  • heart failure; or
  • if you have an infection.

Pregnancy

Camzyos may harm an unborn baby. You may need a pregnancy test to make sure you are not pregnant before using this medicine. Use effective birth control while using this medicine and for at least 4 months after your last dose. Tell your doctor if you become pregnant.

Hormonal contraceptives containing a combination of ethinyl estradiol and norethindrone may be used with this medicine, but it can make other birth control pills less effective. Ask your doctor about all birth control options, such as an injection, implant, skin patch, vaginal ring, condom, diaphragm, cervical cap, or contraceptive sponge.

Breastfeeding

Ask a doctor if it is safe to breastfeed while using this medicine.

How should I take Camzyos?

Take Camzyos once a day.

Swallow the capsule whole. Do not break, open, or chew the capsule.

You will start with an initial dose, and over weeks, your Doctor will increase your dose depending on how you respond to the medicine.

Your healthcare provider may change your dose, temporarily stop, or permanently stop your treatment if you have certain side effects.

Take Camzyos capsules exactly as your healthcare provider tells you to take them.

Do not change your dose without talking to your healthcare provider first.

What happens if I miss a dose?

If you miss a dose, take it as soon as possible and take your next dose at your regularly scheduled time the next day. Do not take 2 doses on the same day to make up for a missed dose.

What happens if I overdose?

If you take too much or overdose, call your healthcare provider or go to the nearest hospital emergency room right away.

Dosing information

Usual Adult Dosage for Hypertrophic Cardiomyopathy

Starting dose: 5 mg orally once a day

  • Reduce starting dosage to 2.5 mg/day in those taking moderate CYP2C19 inhibitors or a strong CYP3A4 inhibitor.
  • See the Camzyos Prescribing Information for complete dosing information and instructions for regular left ventricular ejection fraction (LVEF) and Valsalva left ventricular outflow tract (LVOT) gradient assessment.

Allowable subsequent doses with titration: 2.5, 5, 10, or 15 mg orally once a day.

Available Strengths 

  • 2.5mg, 5mg, 10mg, 15mg capsules.

What other drugs will affect Camzyos?

Tell your doctor about all your other medicines, especially:

  • moderate to strong CYP2C19 inhibitors or strong CYP3A4 inhibitors
  • moderate to strong CYP2C19 inducers or moderate to strong CYP3A4 inducers
  • heart medications such as disopyramide, ranolazine, or verapamil that are taken with a beta blocker, or diltiazem with a beta blocker, as these medications and combinations increase the risk of left ventricular systolic dysfunction and heart failure symptoms
  • other medicines to treat obstructive hypertrophic cardiomyopathy; or
  • omeprazole, esomeprazole, or cimetidine.

Camzyos is an inducer of CYP3A4, CYP2C9, and CYP2C19. Concomitant use with CYP3A4, CYP2C9, or CYP2C19 substrates may reduce the plasma concentration of these drugs. Ask your healthcare provider if you are taking one of these medications. 

Progestin and ethinyl estradiol are CYP3A4 substrates. Concomitant use of Camzyos may decrease blood levels of certain progestins, which may lead to contraceptive failure. Combined hormonal contraceptives (CHCs) containing a combination of ethinyl estradiol and norethindrone may be used, but if other CHCs are used, patients should add nonhormonal contraception (such as condoms) during concomitant use and for 4 months after the last dose of Camzyos.

]]>
https://drugonomy.com/2026/02/13/camzyos/feed/ 0
Calquence https://drugonomy.com/2026/02/13/calquence/ https://drugonomy.com/2026/02/13/calquence/#respond Fri, 13 Feb 2026 09:34:36 +0000 https://drugonomy.com/?p=11302 What is Calquence?

Calquence (acalabrutinib) is a targeted cancer treatment used for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL), in certain patients.

Calquence is a Bruton tyrosine kinase (BTK) inhibitor that works by blocking BTK, a protein that plays a key role in cancer cell growth and division. By inhibiting BTK, Calquence helps to slow the progression of cancer and helps extend patients’ lives

Calquence capsules and tablets are taken twice daily.

Calquence FDA approval was granted on October 31, 2017, for treating MCL. Its approval was later expanded to include CLL and SLL. Calquence is manufactured by AstraZeneca Pharmaceuticals.

How does Calquence work? 

Some cancer cells get signals to grow and divide from a protein called Bruton tyrosine kinase (BTK). The Calquence mechanism of action is by blocking Bruton tyrosine kinase (BTK), which helps to stop cancer cells from growing and multiplying, to help reduce cancer growth. The Calquence class of medications is called BTK inhibitors and is a targeted therapy.

Is Calquence chemotherapy?

No, Calquence is not chemotherapy; it is a targeted therapy, specifically a Bruton’s tyrosine kinase (BTK) inhibitor.

What is Calquence used for?

Calquence is used for adult patients with:

  • chronic lymphocytic leukemia (CLL)
  • small lymphocytic lymphoma (SLL) 
  • mantle cell lymphoma (MCL)  in patients
    • who have received at least one prior therapy, or
    • who are previously untreated, and
      • are ineligible for autologous hematopoietic stem cell transplantation (HSCT), and
      • used in combination with bendamustine and rituximab.

Calquence side effects

Common Calquence side effects

Common Calquence side effects include:

  • Infection (65%)
  • Upper respiratory tract infection – URTI (35%)
  • Lower respiratory tract infection – LRTI (18%)
  • Urinary tract infection – UTI (15%)
  • Headache (39%)
  • Dizziness (20%)
  • Diarrhea (35%)
  • Nausea (22%)
  • Musculoskeletal pain (32%)
  • Joint pain (16%)
  • Tiredness (23%)
  • Bruising (21%)
  • Rash (25%)
  • Hemorrhage (20%).

There were also changes in blood test levels neutropenia 23% (low white blood cells), anemia 53% (low red blood cells), thrombocytopenia 32% (low platelet levels, and lymphocytosis 16% (high white blood cells).

The above common side effects occurred in patients being treated with Calquence CLL as monotherapy and occurred in 15% or more of patients.

Serious side effects

Calquence may cause serious side effects. Call your doctor at once if you have:

  • unusual bleeding – nosebleeds, bleeding gums, abnormal vaginal bleeding, any bleeding that will not stop
  • bleeding inside your body – weakness, dizziness, confusion; problems with speech, prolonged headache, bloody or tarry stools, pink or brown urine; coughing up blood or vomit that looks like coffee grounds
  • heart rhythm disorders – dizziness, chest pain, shortness of breath, fast or irregular heart rate, or feeling light-headed. Serious cardiac arrhythmias have occurred in patients treated with Calquence
  • low blood cell counts – fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath
  • signs of infection – fever, chills, tiredness, flu-like symptoms, cough with mucus, chest pain, trouble breathing.

Get emergency medical help if you have signs of an allergic reaction to Calquence hives, difficulty breathing, or swelling of your face, lips, tongue, or throat.

This medicine may cause a brain infection that can lead to disability or death. Tell your doctor if you have problems with speech, thought, vision, or muscle movement. These symptoms can get worse quickly.

Liver toxicity, which may be severe or fatal, has been reported with Bruton tyrosine kinase inhibitors, including this medicine. Your healthcare provider will monitor your liver function tests before starting treatment with this medicine and while you are taking it. Tell your healthcare provider immediately if you experience abdominal discomfort, dark urine, or yellowing of the skin.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects.

Warnings

Bleeding problems. Calquence can make it easier for you to bleed. Contact your doctor or seek emergency medical attention if you have any bleeding that will not stop.

Call your doctor at once if you have signs of bleeding inside your body, such as: dizziness, weakness, confusion, headache, speech problems, black or bloody stools, pink or brown urine, or coughing up blood or vomit that looks like coffee grounds.

Your healthcare provider may stop this medicine for any planned medical, surgical, or dental procedure

Infections: Monitor for signs and symptoms of infection and treat promptly. 

Change in blood tests. It may cause low levels of red blood cells (anemia), white blood cells (leukopenia), or platelets (thrombocytopenia). You will have complete blood counts regularly.

Second Primary Cancer: Other cancers have occurred, including skin cancers and other solid tumors. Always use sun protection. 

Heart rhythm changes: You will be monitored for symptoms of problems with the rate or rhythm of your heart (arrhythmias).

Severe hepatic impairment. This medicine should be avoided in patients with severe liver impairment and liver problems that have occurred in patients taking this medicine. If you have symptoms of stomach pain, dark-colored urine of dark color, or yellowing of your skin, you should contact your healthcare provider, who will monitor your liver function.

Before taking this medicine

To make sure Calquence is safe for you, tell your doctor if you have ever had:

  • an active or chronic infection, including hepatitis B;
  • a heart rhythm disorder;
  • bleeding problems;
  • recent surgery or plan to have surgery, medical or dental procedure; or
  • liver problems

Taking Calquence may increase your risk of developing other cancers. Ask your doctor about this risk.

Pregnancy

Tell your healthcare professional if you are pregnant or plan to become pregnant, as Calquence may harm your unborn baby and problems during childbirth (dystocia). Your healthcare provider may do a pregnancy test before you start treatment, if you are able to become pregnant.

Females who are able to become pregnant should use effective birth control (contraception) during treatment with this medicine and for at least 1 week after the last dose.

Breastfeeding

Tell your healthcare professional if you are breastfeeding or plan to breastfeed. It is not known if Calquence passes into your breast milk. Do not breastfeed during treatment with this medicine and for at least 2 weeks after your final dose.

How should I take Calquence?

Calquence directions

  • Calquence tablet and capsules is usually taken twice per day (about 12 hours apart) with or without food, with a glass of water. Swallow the tablet and capsule whole, and do not crush, chew, break, open, or dissolve it.
  • If you need to take an antacid medicine, take it either 2 hours before or 2 hours after you take Calquence.  If you need to take certain other medicines called acid reducers (H-2 receptor blockers), take Calquence 2 hours before the acid reducer medicine.
  • Your healthcare provider may tell you to decrease your dose, temporarily stop, or completely stop taking this medicine if you develop certain side effects. 
  • Take this medicine exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets. Your doctor may occasionally change your dose.
  • If you need surgery, tell the surgeon beforehand that you are using this medication. You may need to stop using the medicine for a short time.
  • While taking this medicine, you may need frequent blood tests.
  • If you’ve had hepatitis B, it may come back. You may need liver function tests while using this medicine.

Calquence dosing information

Usual monotherapy adult dose of Calquence for CLL,  SLL, or MCL

Dose: Calquence 100 mg capsule or tablet orally every 12 hours until the cancer progresses or there is unacceptable toxicity.

Usual adult dose in combination with obinutuzumab 

For patients with previously untreated CLL or SLL. The recommended dose of Calquence 100 mg taken orally approximately every 12 hours. Start Calquence at Cycle 1 (each cycle is 28 days). Start obinutuzumab (Gazyva) at Cycle 2 for a total of 6 cycles and refer to the obinutuzumab prescribing information for recommended dosing. 

Administer Calquence prior to obinutuzumab when given on the same day. 

Usual adult Calquence dose in combination with bendamustine and rituximab 

For patients with previously untreated MCL. The recommended dosage of 100 mg taken orally approximately every 12 hours until disease progression or unacceptable toxicity

Start Calquence on Day 1 of Cycle 1 (each cycle is 28 days) 

Administer bendamustine 90 mg/m2 on Days 1 and 2 and rituximab 375 mg/m2 on Day 1 of Cycle 1 and continue for a total of 6 cycles. 

Patients achieving a response (PR or CR) after the first 6 cycles may receive maintenance rituximab on Day 1 of every other cycle for a maximum of 12 additional doses, starting on Cycle 8 up to Cycle 30 

General dose information

How long do you take Calquence? Calquence treatment should be continued until the cancer progresses or there is unacceptable toxicity.

Formulations available: 

  • Calquence 100mg capsules.
  • Calquence 100mg tablets.

Hepatic Impairment. You should not take this medicine if you have severe hepatic impairment. Dose modifications are not required for patients with mild or moderate hepatic impairment.

Dose modifications for drug interactions. See detailed dosing information for dose modifications required for drug interactions.

What happens if I miss a dose?

Take the medicine as soon as you can, but skip the missed dose if you are more than 3 hours late for the dose. Do not use two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line .

What should I avoid while taking Calquence?

Avoid taking an antacid such as Tums or calcium carbonate within 2 hours before or after you take Calquence.

Calquence could make you sunburn more easily. Avoid sunlight or tanning beds. Wear protective clothing and use sunscreen (SPF 30 or higher) when you are outdoors.

What other drugs will affect Calquence?

Sometimes it is not safe to use certain medicines at the same time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.

Drug interactions with groups:

  • Strong CYP3A Inhibitors: Avoid co-administration of strong CYP3A Inhibitors with Calquence.
  • Moderate CYP3A Inhibitors: Reduce the dosage of Calquence if these medicines are used together.
  • Strong CYP3A Inducers: Avoid co-administration of strong CYP3A Inducers with Calquence. If co-administration is unavoidable, then the dosage of Calquence should be increased.

If you use a stomach acid reducer such as cimetidine, ranitidine, Tagamet, Pepcid, or Zantac, take the Calquence dose 2 hours before taking any of these other medicines.

Tell your doctor about all your current medicines. Many drugs can affect acalabrutinib, especially:

  • a blood thinner (warfarin, Coumadin, Jantoven);
  • an antibiotic or antifungal medicine (itraconazole, fluconazole, erythromycin, rifampin);
  • antiviral medicine to treat hepatitis C or HIV/AIDS;
  • heart medication (diltiazem) ; or
  • a proton pump inhibitor stomach acid medicine – such as omeprazole, lansoprazole, rabeprazole, Nexium, Prevacid, Prilosec, Protonix, and others.

This list is not complete and many other drugs may interact with acalabrutinib. This includes prescription and over-the-counter medicines, vitamins, and herbal products.

Calquence Copay Card and Calquence Cares

The Calquence Copay Card can help you pay as little as $0 per month for out-of-pocket costs if you have commercial insurance plans.

AstraZeneca has a support program called AstraZeneca Access 360, which can help with questions about insurance, costs, affordability options, and other patient resources.

For patients with Medicare or no insurance facing affordability challenges, there is also an AstraZeneca Prescriptions Savings plan called AZ&ME.

Calquence Package Insert 

Review the Calquence Package Insert (PI) for more detailed information about this medicine. The PI contains more comprehensive information on Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies, Drug Interaction, and more. Discuss any medical questions you have with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.

]]>
https://drugonomy.com/2026/02/13/calquence/feed/ 0